Linagliptin

Nomen chemicum:

8-[(3R) -3-aminopiperidin-1-yl]-7-(sed-2-yn-1-yl) -3- methyl-1-[(4-methylquinazolin-2-yl) methyl]-3 ,7-dihydro-1H-purine-2,6-dione

SMILES Code:

O=C(N1CC2=NC(C)=C3C=CC=CC3=N2)N(C)C4=C(N(CC#CC)C(N5C[C@H](N)CCC5)=N4)C1 = O

InChi Code:

InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35) 33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9; 12-15,26H2,1-3H3/t17-/m1/s1

InChi Key:

LTXREWYXXSTFRX-QGZVFWFLSA-N

Keyword:

Linagliptin, BI-1356, BI 1356, BI1356, 668270-12-0

Solubilitas:Solutum in DMSO

Repono:0 - 4°C ad terminum brevem (dies ad septimanas), vel -20°C ad terminum longi (menses).

Descriptio:

Linagliptin, etiam BI-1356 notum, est DPP-IV inhibitor a Boehringer Ingelheim enucleatus ad tractationem speciei II diabete. Linagliptin (olim-die) ab US FDA probatus est die 2 mensis Maii anno 2011 ad tractationem speciei II diabete. Apud Boehringer Ingelheim et Lilium venales est.

Target: DPP-4